Skip to main content

MLH1

Function

Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.

Involvement in disease

Lynch syndrome 2

LYNCH2

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

None

The disease is caused by variants affecting the gene represented in this entry.

Mismatch repair cancer syndrome 1

MMRCS1

An autosomal recessive form of mismatch repair cancer syndrome, a childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer.

None

The disease is caused by variants affecting the gene represented in this entry.

Muir-Torre syndrome

MRTES

Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.

None

The disease is caused by variants affecting the gene represented in this entry.

Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.

Endometrial cancer

ENDMC

A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by Lynch syndrome but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.

Colorectal cancer

CRC

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Sequence similarities

Belongs to the DNA mismatch repair MutL/HexB family.

Tissue specificity

Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.

Cellular localization

  • Nucleus
  • Chromosome
  • Recruited to chromatin in a MCM9-dependent manner.

Alternative names

  • COCA2
  • COCA2
  • MLH1
  • DNA mismatch repair protein Mlh1
  • MutL protein homolog 1

Target type

Proteins

Primary research area

Oncology

Other research areas

  • Immuno-oncology

Molecular weight

84601Da

We found 36 products in 4 categories

Proteins & Peptides

Target

Species of origin

Nature

Multiplex Kits

Target

Cell Lines & Lysates

Target

Cell type

Species or organism

Search our catalogue for 'MLH1' (36)

Products

ab92312

Anti-MLH1 antibody [EPR3894]

Recombinant
RabMAb
KO Validated

ab223844

Anti-MLH1 antibody [EPR20522]

Recombinant
RabMAb
KO Validated

ab108622

Anti-MLH1 antibody [EPR3893]

Recombinant
RabMAb
KO Validated

ab229191

Anti-MLH1 antibody [EPR20741]

Recombinant
RabMAb

ab214441

Anti-MLH1 antibody [EPR3894] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab251576

Anti-MLH1 antibody [EPR20522] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab247703

Anti-MLH1 antibody [EPR3893] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab267223

Human MLH1 knockout HeLa cell line

Advanced Validation

ab276105

Human MLH1 knockout A549 cell line

Advanced Validation

ab303188

APC Anti-MLH1 antibody [EPR20522]

Recombinant
RabMAb